Back to top
more

CytRx Corporation (CYTR)

(Delayed Data from NSDQ)

$0.51 USD

0.51
138,568

-0.02 (-3.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

LadRx Corporation [CYTR]

Reports for Purchase

Showing records 1 - 20 ( 99 total )

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

01/12/2020

Company Report

Pages: 4

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CYTR

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

02/05/2019

Company Report

Pages: 5

Arimoclomol Edges Closer to Potential Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

01/04/2019

Company Report

Pages: 4

Preclinical Development Phase Concludes; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

11/05/2018

Company Report

Pages: 4

3Q18 Financial Results Reported; Cash Burn Rapidly Declining; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

08/07/2018

Company Report

Pages: 4

2Q18 Financial Results Reported; Looking Ahead to Potential LADR Partnership; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

07/26/2018

Company Report

Pages: 4

Provisional Patent Application Filed for Companion Diagnostic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

06/05/2018

Company Report

Pages: 4

Centurion BioPharma Formed to Unlock Potential of LADR- Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

05/23/2018

Company Report

Pages: 4

1Q 2018 Financial Results Reported; Cash Replenished; Reiterate Buy and Raising Target to $4.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

05/03/2018

Company Report

Pages: 18

A Leaner, Meaner CytRx; Assuming Coverage at Buy and $4 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 50.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

04/20/2017

Daily Note

Pages: 3

Clarity on Regulatory Pathway Rekindles Aldox Value Proposition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

01/20/2017

Company Report

Pages: 7

Our Thoughts on the Next Steps for Aldox

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

04/22/2016

Company Report

Pages: 7

Pivotal Phase 3 Sarcoma Data Expected this Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

12/11/2015

Industry Report

Pages: 4

Tales from the Epigenetic Backwoods at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

05/05/2015

Company Report

Pages: 7

Interim Phase 1b Data Highlight Aldox Safety and Chemo Add-on Potential

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

03/16/2015

Company Report

Pages: 7

4Q14 Update: Sarcoma Phase 3 Remains on Track, While Company Advances New Aldox Indications

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

10/15/2013

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

10/01/2013

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

09/30/2013

Company Report

Pages: 7

Positive Data and Program Expansions for Aldoxorubicin; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: LadRx Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

08/07/2013

Daily Note

Pages: 13

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party
// eof